News

Engaging pharmacists in healthcare information technology is crucial to increasing overall medication adherence in healthcare, panelists on the “Connected Health, Better Adherence” roundtable at the Pew Conference Center in Washington, DC, told attendees last week.

CVS Caremark is recognizing that cigarettes and pharmacies don't mix and will stop selling cigarettes and other tobacco products at its more than 7,600 CVS/pharmacy stores across the United States by October 1, 2014. This move makes CVS/pharmacy the first national pharmacy chain to take this step in support of the health and well-being of its patients and customers.

Complex diseases present complex challenges for researchers, clinicians, drug manufacturers, and FDA for a variety of reasons. The impact, however, is felt at the patient level, particularly when there are no FDA-approved treatments. In some cases, such as myalgic encephalomyelitis, commonly known as chronic fatigue syndrome (ME/CFS), the devastating effects of the disease are exacerbated by the huge deficit in the drug application and approval pipeline. This leaves the patient population with little hope.

Researchers recently determined that acute otitis media is associated with an incremental increase in outpatient health care costs of $314 per child per year in the United States, which translates into approximately $2.88 billion in added health care expense annually.

Anti-muscarinic drugs are an option in the treatment of overactive bladder which is defined as urinary urgency with or without urge incontinence, usually accompanied by frequency and nocturia, in the absence of a urinary tract infection or other obvious pathology.Oral oxybutynin has been available by prescription for over 40 years, initially marketed as Ditropan® and Ditropan XL® although now generically availably, in addition to the transdermal patch Oxytrol and transdermal gel Gelnique. As an antagonist at muscarinic receptors, oxybutynin leads to relaxation of the smooth muscle of the bladder which leads to increased bladder capacity, decreased involuntary contractions and decreased urgency and frequency of both voluntary and incontinent episodes. The suggested dose is one patch applied for 4 consecutive days, after which the patch should be removed and a new one applied.

Two oncologists are calling on fellow oncologists and the American Society of Clinical Oncology (ASCO) to support a single-payer healthcare system, according to an article published in the January issue of the Journal of Oncology Practice.